The aim of this work is to compare Bayesian Inference methods with commonly used non-linear regression (NR) algorithms for estimating pharmacokinetics in Dynamic Contrast Enhanced Magnetic Resonance Imaging (DCE-MRI). The algorithms are compared in terms of accuracy, and reproducibility under different initialization settings. Further it is investigated how a more robust estimation of pharmacokinetics affects cancer diagnosis. The derived pharmacokinetics from the Bayesian inference algorithm were validated against NR algorithms (i.e. Levenberg-Marquardt, simplex) in terms of accuracy on a digital DCE phantom and in terms of goodnessof-fit (Kolmogorov-Smirnov test) on ROI-based concentration time courses from two different patient cohorts. The first cohort consisted of 76 men, 20 of whom had significant peripheral zone prostate cancer (any cancer-core-length (CCL) with Gleason>3+3 or any-grade with CCL>=4mm) following transperineal template prostate mapping biopsy. The second cohort consisted of 9 healthy volunteers and 24 patients with head and neck squamous cell carcinoma. The diagnostic ability of the derived pharmacokinetics was assessed with receiver operating characteristic area under curve (ROC AUC) analysis. The Bayesian inference algorithm accurately recovered the ground-truth pharmacokinetics for the digital DCE phantom consistently improving the Structural Similarity Index (SSIM) across the 50 different initializations compared to NR. For optimized initialization, Bayesian inference did not improve significantly the fitting accuracy on both patient cohorts, and it only significantly improved the ve ROC AUC on the HN population from ROC AUC=0.56 for the simplex to ROC AUC=0.76. For both cohorts, the values and the diagnostic ability of pharmacokinetic parameters estimated with Bayesian Inference weren't affected by their initialization. To conclude, the Bayesian inference led to a more accurate and reproducible quantification of pharmacokinetic parameters in DCE-MRI, improving their ROC-AUC and decreasing their dependence on initialization settings.
Introduction
Dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI) is influenced by the micro-vascular characteristics of tissue, such as blood flow/volume, surface area/permeability of vessel walls, and micro-vascular density. These characteristics are associated with the expression of potent cytokines (such as the vascular endothelial growth factor) that support the development of tumor vessels. This makes DCE-MRI a valuable diagnostic tool in oncology. The purpose of this study is to investigate whether accurate quantification of pharmacokinetic parameters using the proposed Bayesian Inference algorithm can improve cancer diagnosis compared to non-linear regression fitting algorithms.
Quantification of pharmacokinetic parameters is affected by field inhomogeneities, gradients, SNR of the reconstructed images, and spatiotemporal resolution [1] . Besides limitations in acquisition, quantification of pharmacokinetic parameters will depend on the selection of pharmacokinetic model, the accurate estimation of the arterial input function, the estimation of the native T1 of the tissue [2] and the selection of fitting algorithm. Heyes et al [ [3] , [4] ] studied the variation within-and between workstations in the derivation of pharmacokinetic parameters and reported a 25.1%-74.1% within-subject coefficient of variation. The conclusion of these studies is that unless the contrast agent material, the definition of AIF, the image SNR, and the fitting process are standardized DCE MRI related parameters will not be reproducible. Pharmacokinetic models such as the extended Toft model [5] that describe the enhancement process are often used to derive quantitative parameters and are increasingly used in diagnostic models [6] including computer aided diagnostic (CAD) software [ [7] , [8] ]. Accurate quantification that will be reproducible between different clinical sites is necessary for the widespread of DCE based CAD software. This work will investigate how the optimization process itself can affect the quantification and the diagnostic ability of the quantified parameters..
Quantitative DCE parameters are usually extracted by fitting the estimated concentration to the measured concentration time course, using algorithms such as non-linear least squares or the simplex algorithm. These fitting algorithms are prone to hit local minima [9] resulting in fitting errors and fitted parameters that depend on their initialization. To the best of our knowledge there are no guidelines on how to initialize the pharmacokinetics, and its clinical site uses its own initialization settings. Consequently there is a clear need to develop robust fitting strategies that will not be affected by the initialization of the pharmacokinetics.
To overcome these issues, Bayesian inference algorithms were suggested [ [10] , [11] , [12] ]. Bayesian inference algorithms can model the noise of the measured concentration of the contrast agent and have a theoretical guarantee to converge if run long enough [13] . This work suggests a Bayesian inference algorithm similar to the ones proposed by other groups [ [10] , [11] , [12] ] and evaluates its robustness and diagnostic value against the Levenberg-Marquardt and the simplex algorithms on two separate cohorts of patients:
i) a cohort of 76 men, 20 of whom had significant prostate cancer in the peripheral zone ii) a cohort of 9 healthy volunteers and 24 patients with squamous cell carcinoma.
The proposed Bayesian inference algorithm is described in the theory section. The robustness value is assessed based on goodness-of-fit, and how robust the algorithm is when using different initialization settings of the estimated pharmacokinetic parameters. Receiver operating characteristic (ROC) analysis is performed on the derived pharmacokinetics to assess their ability to classify significant cancer.
Theory

Pharmacokinetic Modeling
A pharmacokinetic analysis was performed by fitting the extended Toft [5] (Eq. 1) modelled concentration (t) (mmol/L) to the concentration time course (t) (Eq. 2).
Where (t) is the arterial input function (mmol/L), is the blood plasma volume fraction, is the transfer constant between plasma and interstitial space (min -1 ), is the interstitial space volume and 0 is the arrival time of the bolus at the tissue (secs). Population arterial input function was used [15] .
The concentration time course was calculated from the image signal intensities (t) using the approximation Repetition time⪡T1
Where 1 is the in-vivo relaxivity (4.51 L mmol -1 sec -1 ), 10 is the native T1 of the tissue before contrast agent injection, calculated from a multiple flip angle dataset (sec), and 0 is the average of the acquired images before the injection of the contrast agent.
Non linear regression algorithms
Pharmacokinetic models are fitted with two commonly used non-linear regression algorithms i.e. the Levenberg-Marquardt and the simplex algorithm. Levenberg-Marquardt is a least squares curve fitting algorithm that is a blend between the Gauss-Newton and the gradient descent method. The update rule of the pharmacokinetics parameters is: k i+1 =k i -(H+λI) -1 ∇L(k i ), where H is the Hessian matrix at k i , λ is a regularization parameter and L is the likelihood function to be minimized i.e. L(k i )=∑ ( (t) − (t)) 2 . When the likelihood is decreased λ is also reduced, but if the likelihood is increased λ will also be increased to reduce the influence of gradient descent. Contrary to other gradient based methods Levenberg-Marquardt is not performing a line minimization (where the direction of gradient descent is decided prior to step size estimation) hence requires less likelihood evaluations reducing the computational cost.
The simplex algorithm is also an iterative procedure but unlike the Levenberg-Marquardt does not require derivative information. The algorithm will create a "random" simplex of n+1 points, where n is the number dimensions (number of pharmacokinetic parameters to be estimated). The simplex moves iteratively by reflection, expansion or contraction steps trying to find the pharmacokinetic parameters that minimize the likelihood function. In this work we used a constrained variation of the simplex algorithm [ [16] , [17] ] and an ℓ1-norm in the likelihood function to improve robustness [18] . Simplex algorithm is particularly advantageous in cases where the gradient of the likelihood functions is hard to calculate.
Bayesian inference algorithm
In the proposed Bayesian Inference algorithm the measured concentration (t) is modelled using additive Gaussian noise σ and the pharmacokinetic parameters, k= {vp, Ktrans, ve, t0} for the extended Tofts model or k= { γ, Ktrans, ve, t0} for the Orton model
The suggested Bayesian inference algorithm similar to [[10] , [11] , [12] ] maximizes the posterior 
Where p(CTIC|k,σ) is the likelihood function of CTIC given the pharmacokinetic parameters k,
and p(k,σ) is the product of the prior probability distribution functions of k and σ, (k, σ).
Prior probability distribution functions reflect our prior knowledge about the k and σ parameters. We assume the subsequent prior distributions for every pharmacokinetic parameter  vp follows a Beta distribution, vp~Beta (1, 19) [19] reflecting an a priori expected value of 0.05. The integral ∫ ( * , * ) • ( | * , * ) * , * is estimated with the Metropolis-Hastings algorithm.
Materials and methods
Generate Simulated DCE data
The DCE simulation used is similar to the one published from our group in Dikaios et al 
Where  is the proton density image, and was calculated analytically using Eq. 8 from the T1weighted abdominal image without contrast injection and the graund truth T10 maps.
DCE images were transformed to (k, t)-space with fast Fourier transformation where noise was added. The noise of complex valued (k, t)-space MR data can be reasonably modelled by an additive white Gaussian distribution on both real and imaginary components (independent and identically distributed random variables). Simulated DCE data were generated for 2 different noise levels , one corresponding to the average SNR before contrast injection of prostate T1w images (SNR~9.2, noise level=2500) and a separate one corresponding to the average SNR before contrast injection of neck T1w images (SNR~15.1, noise level=800). The SNRs were calculated as described in Dikaios et al [21] .
Patient populations
Institutional review board (IRB) approval for the study was obtained. The requirement for consent was waived for use of images acquired in routine clinical practice (prostate peripheral zone population) and obtained from all patients undergoing imaging as part of a separate clinical trial (head and neck population).
Prostate population
The [26] . Equivocal nodes were sampled at the time of ultrasound by fine needle aspiration (FNA) and classified by in-room cytology. For the proposed Bayesian inference algorithm the total number of iterations was 500, burn-in iterations were 300, thinning equal to 5, and tune iteration (number of iterations for tuning) was 67. Leave-one-out analysis [21] was used for internal validation of predictive models. One case (out of the total patient population) was excluded, and a model generated from the remainder of the cases. The model was then tested on the excluded case and a predictive probability calculated. The process was repeated for all cases, excluding successive cases in turn allowing calculation of a predictive probability per case. An ROC (LOO ROC) was then created using the derived predictive probabilities. ROC curves were compared using the significance test suggested by Hanley and McNeil [27] . algorithm has similar performance to the Levenberg-Marquardt (LM), with marginally higher SSIM. Fig. 1 provides a visual comparison between the pharmacokinetics maps estimated with the simplex and the Bayesian algorithm.
Optimization details of the fitting algorithms
Statistical analysis
Results
Simulated DCE data
Fig. 1
Parametric maps (vp, Ktrans, ve, t0) estimated with pixel-by-pixel fitting of the simulated DCE images with SNR=9.2 using the simplex and the Bayesian inference algorithms. Ground truth pharmacokinetics maps are shown at the top row. 
Prostate population
Multiple initialisations -Robustness of evaluated algorithms
The simplex, the Levenberg-Marquardt and the Bayesian inference algorithms were all run with the same 50 different initializations, Fig. 2 shows the KS test statistic (across the 76 mean ROI profiles of the PZ prostate population) for each initialization. The interquartile range of the medians was 0.019 for the simplex algorithm, 0.018 for the Levenberg-Marquardt algorithm and 0.002 for the Bayesian inference algorithm. Simplex algorithm had consistently better goodness-of-fit than the Levenberg-Marquardt; hence hereafter the Levenberg-Marquardt was excluded from the comparison. Score test and univariate ROC analysis of the pharmacokinetic parameters derived with the simplex and the Bayesian inference algorithms (using the optimum pharmacokinetic initialization in terms of goodness-of-fit) performed on the whole PZ population and following LOO analysis.
Univariate ROC analysis
Comparison of pharmacokinetic parameters between PZ prostate cancer/benign ROIs
Parametric maps of a PZ prostate cancer patient estimated with the simplex and the Bayesian inference algorithms are illustrated in Fig. 3 . The modelled concentration C(t) is fitted to the mean concentration profile along the PZ prostate cancer ROI CTIC(t) (Fig. 3 ). In Fig. 3 , while vp values estimated from the cancer ROI profile are almost zero for the simplex algorithm, following pixel-by-pixel fitting the cancer area in the vp seems to be slightly higher than zero.
Pharmacokinetic parameters estimated by fitting mean ROI profiles will not necessarily of an ROI and propagating it in time will generate a "smooth" profile, resulting in an approximated time-intensity curve. Ideally pixel-by-pixel fitting needs to be performed, but because it is more computationally demanding many clinical papers resort to mean ROI profile fitting.
Following MWU test, none of the pharmacokinetic parameters estimated with the Bayesian inference algorithm were significantly different from the ones estimated with the simplex algorithm for either the benign or the cancer ROIs (Fig. 4) . Pharmacokinetic maps (vp, Ktrans, ve) estimated with pixel-by-pixel fitting using the simplex and the Bayesian inference algorithms for a PZ prostate cancer patient. A plot of the mean ROI concentration profile (t) and the fitted to curve using the simplex and the Bayesian inference algorithms is also shown.
Fig. 4
Boxplot diagram of the pharmacokinetic parameters derived with the simplex and the proposed Bayesian inference algorithm, performed separately for the normal and cancer PZ prostate ROIs.
The terms in brackets refer to the median value (interquartile range) of the estimated pharmacokinetic parameters.
Head and Neck population
Multiple initialisations -Robustness of evaluated algorithms
The simplex, the Levenberg-Marquardt and the Bayesian inference algorithms were all run with the same 50 different initializations, Fig. 5 shows the median KS statistic test (across the 33 mean ROI profiles of the head and neck patients and volunteers) for each initialization. The interquartile range of the medians was 0.0083 for the simplex algorithm, 0.010 for the Levenberg-consistently better goodness-of-fit than the Levenberg-Marquardt; hence from hereafter the Levenberg-Marquardt was excluded from the comparison.
Fig. 5
Plot of the median KS statistic test (median KS statistic test across the 33 mean ROI head and neck profiles) across the 50 different initializations for the simplex and the Bayesian inference algorithms. The interquartile range (iQR) of the median KS statistic test is 0.010 for the Levenberg-Marquardt, 0.0083 for the simplex and 0.0021 for the Bayesian inference algorithm. Table 3 shows the ROC analysis of the pharmacokinetic parameters estimated with the simplex and the Bayesian inference algorithms using the optimum pharmacokinetic initialization in terms of goodness-of-fit. Ktrans was the best classifier of head and neck metastatic patients for both the simplex and the Bayesian inference algorithms. According to the score test, for the simplex algorithm only Ktrans could significantly classify metastatic patients, whereas for the Bayesian inference both Ktrans and ve were significant classifiers (table 3) .
Univariate ROC analysis
Following a significance test between ROC curves, the AUC (on the original population or following LOO analysis) of Ktrans, estimated with the Bayesian inference algorithm, was not significantly better. Significant difference was only found for the ve AUC between the simplex and the Bayesian inference algorithms (table 3) .
The simplex and the Bayesian inference algorithms were run with different initializations Box-plot diagram of the pharmacokinetic parameters derived with the simplex and the proposed Bayesian inference algorithms, performed separately for the benign and metastatic neck node
ROIs. The terms in brackets refer to the median value (interquartile range) of the estimated pharmacokinetic parameters. Asterisk (*) denotes significant difference (p<0.05) between the simplex and Bayesian inference algorithms.
Discussion
This works aims to investigate the diagnostic benefits of using Bayesian Inference algorithms for the derivation of pharmacokinetic parameters in DCE-MRI. The proposed Bayesian Inference algorithm is compared against non-linear regression algorithms (i.e.
Levenberg-Marquardt and simplex) in terms of accuracy, reproducibility under different initialization settings and ability to classify cancer.
The simplex algorithm had consistently marginally higher SSIM with the ground truth kinetics of the simulated DCE phantom and better goodness-of-fit for the ROI-based TIC of both populations than the Levenberg-Marquardt, which could be attributed to its convergence properties [17] . Unlike the Levenberg-Marquardt, the simplex algorithm does not use gradients, which provides some resilience to noise and local minima.
When running the proposed Bayesian inference algorithms for different initializations we found that i. The SSIM with the ground truth pharmacokinetic maps for the Bayesian inference algorithm was consistently higher than for the non-linear regression algorithms for all initializations.
ii Bayesian inference algorithms have been proposed before in the literature [ [10] , [11] , [12] ] to estimate unbiased quantitative pharmacokinetic parameters. The proposed scheme is similar to the one suggested by Schmid et al [10] , the main difference is on the estimation of the onset time. The accuracy of the estimated pharmacokinetic parameters will depend on the arrival time of the contrast agent to the tissue (onset time) [28] . Schmidt et al [7] calculated the onset time as the minimum time t*, for which the contrast concentration significantly exceeds zero minus C(t*)/tC(t*). For the simulated DCE phantom with SNR=9.2, the SSIM index of the onset time calculated with the method of Schmidt et al [10] is 0.5754, whereas for the proposed Bayesian algorithm the respective SSIM is 0.76 (Table 1 ). This affected the estimation of the pharmacokinetic parameters, but if the same onset time was used the Bayesian method suggested by Schmid et al [10] has similar performance with the one proposed in this work. This is expected since both use the Metropolis-Hastings Markov chain Monte Carlo (MCMC) method and similar prior information. Their only difference is that we parameterized the posterior probability distribution function p(k,σ|CTIC) with ve to optimize EES volume directly instead of calculating it via kep (ve=Ktrans/kep) [7] .
Limitations
For the PZ prostate population, we were reliant upon visual matching of the Barzell zone histology on TPM with the ROIs on the mp-MRI. Therefore, results may be influenced by mis-registration errors. Although no biopsy is free from sampling error [29] we used TPM to address as much of the systematic error inherent to transrectal ultrasound (TRUS) guided biopsy as possible [ [29] , [30] ]. For the head and neck population there was a relatively small sample size. We took great care to be certain about positive and negative disease status within individual nodes by recruiting patients with N2/3 disease confirmed by CT, MRI and US ± FNA.
Conclusions
DCE MRI pharmacokinetic parameters are increasingly used in clinical practice; their diagnostic ability will depend on their accurate and reproducible quantification. The proposed Bayesian inference algorithm has been shown in this work to improve the diagnostic ability compared to the simplex algorithm and was robust when different initializations of the pharmacokinetic parameters were used. These assets of the algorithm are essential to train and validate robust CAD software based on DCE-MRI that could be used between different sites. The performance of the Bayesian inference algorithm was consistent on two different populations, acquired with different settings.
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